The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.
%0 Journal Article
%1 sexton_new_2004
%A Sexton, Kerry
%A Lennon, Diana
%A Oster, Philipp
%A Crengle, Sue
%A Martin, Diana
%A Mulholland, Kim
%A Percival, Teuila
%A Reid, Stewart
%A Stewart, Joanna
%A O'Hallahan, Jane
%D 2004
%J The New Zealand Medical Journal
%K B, Disease Factors Humans, Immunization Infections, Meningococcal Neisseria New Outbreaks, Population Postmarketing, Product Programs, Risk Serogroup Surveillance, Vaccines, Zealand, meningitidis,
%N 1200
%P U1015
%R 15475985
%T The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic
%U http://www.ncbi.nlm.nih.gov/pubmed/15475985
%V 117
%X The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.
@article{sexton_new_2004,
abstract = {The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of {B:4:P1.7b,4} group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine {(MeNZB).} This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Sexton, Kerry and Lennon, Diana and Oster, Philipp and Crengle, Sue and Martin, Diana and Mulholland, Kim and Percival, Teuila and Reid, Stewart and Stewart, Joanna and {O'Hallahan}, Jane},
biburl = {https://www.bibsonomy.org/bibtex/2bd241e17516d5bd994e8cd76e01e2ee6/jelias},
doi = {15475985},
interhash = {ef7fa6df45428151e5c286169bec67e5},
intrahash = {bd241e17516d5bd994e8cd76e01e2ee6},
issn = {1175-8716},
journal = {The New Zealand Medical Journal},
keywords = {B, Disease Factors Humans, Immunization Infections, Meningococcal Neisseria New Outbreaks, Population Postmarketing, Product Programs, Risk Serogroup Surveillance, Vaccines, Zealand, meningitidis,},
month = aug,
note = {{PMID:} 15475985},
number = 1200,
pages = {U1015},
shorttitle = {The New Zealand Meningococcal Vaccine Strategy},
timestamp = {2011-03-11T10:06:47.000+0100},
title = {The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic},
url = {http://www.ncbi.nlm.nih.gov/pubmed/15475985},
volume = 117,
year = 2004
}